Forazapadin Drug Patent Issued in United States

The U.S. Patent and Trademark Office has granted a new composition of matter patent for the drug candidate forazapadin.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a complex three-dimensional molecular compound model, representing pharmaceutical intellectual property. — The U.S. Patent and Trademark Office has issued a composition of matter patent for forazapadin, a drug candidate targeting muscle repair mechanisms. AI Illustration. Upload story photo >

Live Poll

Do you believe long-term pharmaceutical patent protections are currently balanced for the benefit of patients?

The U.S. Patent and Trademark Office issued U.S. Patent No. 12,747,245 for forazapadin, a compound designed to restore muscle repair and regeneration. This patent secures intellectual property protection for the drug through September 6, 2044.

Why it matters

The patent provides essential intellectual property protection for the drug candidate, which targets AAK1 to address muscle health. This milestone supports the company's long-term development and commercialization strategy for the candidate.

U.S. Patent No. 12,747,245 covers the composition of matter for forazapadin, which functions as an AAK1 inhibitor. This intellectual property protection for the compound extends through September 6, 2044.

The players

United States Patent and Trademark Office

This federal agency is responsible for granting U.S. patents and registering trademarks.

The details

The drug candidate focuses on targeting AAK1 to restore muscle repair and regeneration mechanisms in the body. The patent will be listed in the FDA Orange Book, and the company may qualify for a Patent Term Extension after receiving U.S. marketing approval.

The U.S. Patent and Trademark Office issued the patent on October 5, 2026.
A Phase 2 clinical study in adults with FSHD is expected to begin in Q4 2026.
Current patent protection is scheduled to expire on September 6, 2044.

Biotech
Sept. 30
Court Ruled Liquidia Infringed on Patent
Cancer
Sept. 29
Cellectar Biosciences Reported Positive Trial Results
Biotech
Sept. 21
ADARx Pharmaceuticals Targeted $1.74 Billion IPO Valuation

The Tech Race

By securing this patent and preparing for an FDA Orange Book listing, the developer is following a standard industry trajectory for drug commercialization. This process bridges the gap between basic laboratory research and the eventual transition to clinical implementation and market entry.

This development marks a step toward potential new therapies for patients dealing with conditions related to muscle repair and regeneration. While the drug is not yet available, the patent ensures the developer can continue research to potentially bring this treatment to market.

The takeaway

Securing long-term patent protection is a critical milestone for biotech firms seeking to validate their pipeline assets. Investors and patients should monitor the upcoming Phase 2 trial results as the primary indicator of the drug potential.